What should I do if Ixazomib causes an allergic reaction?
As a drug for the treatment of multiple myeloma, although its side effects are relatively controllable, ixazomib may still cause allergic reactions during use.
Once a patient is found to have symptoms of an allergic reaction, such as redness, swelling, blistering or peeling with or without fever, skin itching, rash, difficulty breathing, swallowing or speaking, swelling of the skin surface or tongue or throat, the use of ixazomib should be stopped immediately. This is the first step in managing an allergic reaction to prevent symptoms from getting worse.
After stopping the medication, the patient should seek medical treatment as soon as possible and inform the doctor of the allergy so that the doctor can quickly assess the condition and take appropriate treatment measures. The doctor may give anti-allergic drugs, supportive care, or other necessary medical intervention based on the patient's specific situation.
During and after treatment, patients should closely observe changes in their condition. If the symptoms of allergic reaction continue to worsen or new symptoms appear, such as shortness of breath, rapid heartbeat, drop in blood pressure, etc., you should report it to your doctor immediately so that the treatment plan can be adjusted in time.
Patients who have had an allergic reaction to ixazomib or other similar drugs should exercise extreme caution when using related drugs in the future. Under the guidance of a doctor, allergy testing may be required to assess the patient's risk of allergy and formulate corresponding preventive measures, such as avoiding the use of drugs that may cause allergies and keeping anti-allergy drugs on hand.
Ixazomib may interact with other drugs during use, thereby affecting its efficacy or increasing the risk of adverse reactions. Therefore, when using ixazomib, patients should inform their doctors about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements, so that doctors can assess the risk of drug interactions and adjust treatment plans.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)